| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cardiac Imaging |
1 From the Cardiovascular Magnetic Resonance Center (M.R.P., T.S.E.A., M.D.E., R.M.J., R.J.K.) and Clinical Research Institute (M.R.P., D.E.K., E.F.H., L.K.S., M.H.S.), Duke University Medical Center, 2400 Pratt St, Durham, NC 27705. Received May 1, 2005; revision requested July 6; revision received July 27; accepted August 29; final version accepted November 4. M.R.P. supported in part by an American College of Cardiology/Merck Research Fellowship Award. T.S.E.A. supported in part by a Sarnoff Fellowship Award. R.M.J. supported in part by National Institutes of Health (NIH) grant R01-HL63268. R.J.K. supported in part by NIH grant R01-HL64726. Address correspondence to M.R.P. (e-mail: patel017{at}mc.duke.edu).
Purpose: To retrospectively determine the safety of cardiac magnetic resonance (MR) imaging performed early (<14 days) after coronary stent implantation in patients with acute myocardial infarction (AMI).
Materials and Methods: This HIPPA-compliant study was approved by the institutional review board; the informed consent requirement was waived. Consecutive patients with AMI who underwent cardiac MR imaging (study group) shortly after stent implantation (median, 3 days) were compared with control subjects who did not undergo MR imaging and were matched for clinical factors and angiographic extent of coronary disease. A 1.5-T MR imager was used to evaluate cine function, perfusion, and viability. Rates of death, nonfatal myocardial infarction, or revascularization 30 days and 6 months after stent implantation were compared with 
2 analysis.
Results: The study group consisted of 66 patients (median age, 56 years; 17 women) with 97 stents, 38 (39%) of which were drug eluting. The control group included 124 patients (median age, 58 years; 23% women) with 197 stents, 21 (10.7%) of which were drug eluting. There was no significant (P = .13) difference in the combined end point of death, nonfatal myocardial infarction, or revascularization between the study (2.0% [95% confidence interval: 0.0%, 4.5%]) and control (6.5% [95% confidence interval: 1.6%, 11.3%]) groups at 30-day follow-up. The event-free survival rate at 6-month follow-up was 91% in the study group and 83.7% in the control group (P = .18). Considering the end points separately, there was no difference in the event rate at 30-day or 6-month follow-up between groups. No adverse cardiovascular events occurred in patients with drug-eluting stents who underwent MR imaging.
Conclusion: Cardiac MR imaging performed shortly after AMI and percutaneous revascularization with bare metal or drug-eluting stents appears safe. The risk of adverse cardiovascular events is low and similar to that in patients who do not undergo MR imaging.
© RSNA, 2006
This article has been cited by other articles:
|
|
 |
|
  G. N. Levine, A. S. Gomes, A. E. Arai, D. A. Bluemke, S. D. Flamm, E. Kanal, W. J. Manning, E. T. Martin, J. M. Smith, N. Wilke, et al. Safety of Magnetic Resonance Imaging in Patients With Cardiovascular Devices: An American Heart Association Scientific Statement From the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: Endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance Circulation, December 11, 2007; 116(24): 2878 - 2891. [Abstract] [Full Text] [PDF]
|
|
